We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > alzheon

News List

Second time lucky? Alzheon tries for much-reduced IPO fiercebiotech
August 29, 2018
Alzheon is planning a phase 2b trial.
Alzheon says data back plans for phase 3 program fiercebiotech
July 26, 2018
Alzheon is still trying to build a case for a pivotal trial of its Alzheimer’s candidate, and the company says it has new data backing up the drug’s use in patients genetically predisposed to develop the disease.
Alzheon Launches IPO to Fund Alzheimer's Drug biospace
March 20, 2018
Alzheon, based in Framingham, Massachusetts, has filed with the U.S. Securities and Exchange Commission (SEC) to launch an initial public offering (IPO).
Alzheon to present new clinical data and analyses for ALZ-801 cphi-online
February 16, 2017
The presentations highlight Alzheon’s ‘precision medicine’ approach to drug development for Alzheimer’s disease.